Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series

por Nikanjam, Mina, Mullen, Jaren, Yacoub, Carol, Daniels, Gregory A.
Publicado 2022

Pigmentary retinopathy associated with immune therapy for advanced cutaneous melanoma

por Lin, Andrew C., Park, Soo J., Daniels, Gregory A., Borooah, Shyamanga
Publicado 2023

Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review

por McDonald, Marin A., Sanghvi, Parag, Bykowski, Julie, Daniels, Gregory A.
Publicado 2018

Challenge of immune-mediated adverse reactions in the emergency department

por Daniels, Gregory A, Guerrera, Angela D, Katz, Donna, Viets-Upchurch, Jayne
Publicado 2019

Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation

por Chang, Victoria A., Simpson, Daniel R., Daniels, Gregory A., Piccioni, David E.
Publicado 2018

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates

por Wong, Michael K, Daniels, Gregory A, Kaufman, Howard L, McDermott, David F, Morse, Michael A, Aung, Sandra, Lowder, James N
Publicado 2013

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes

por Wong, Michael K, Kaufman, Howard L, Daniels, Gregory A, McDermott, David F, Aung, Sandra, Lowder, James N, Morse, Michael A
Publicado 2014

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)

por Kaufman, Howard L., Wong, Michael K., Daniels, Gregory A., McDermott, David F., Aung, Sandra, Lowder, James N., Morse, Michael A.
Publicado 2014

Cyclin alterations in diverse cancers: outcome and co-amplification network

por Schwaederlé, Maria, Daniels, Gregory A., Piccioni, David E., Fanta, Paul T., Schwab, Richard B., Shimabukuro, Kelly A., Parker, Barbara A., Kurzrock, Razelle
Publicado 2014

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics

por Kato, Shumei, Schwaederle, Maria, Daniels, Gregory A, Piccioni, David, Kesari, Santosh, Bazhenova, Lyudmila, Shimabukuro, Kelly, Parker, Barbara A, Fanta, Paul, Kurzrock, Razelle
Publicado 2015

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies

por Goodman, Aaron M., Kato, Shumei, Cohen, Philip R., Boichard, Amélie, Frampton, Garrett, Miller, Vincent, Stephens, Philip J., Daniels, Gregory A., Kurzrock, Razelle
Publicado 2017

Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients

por Porter, Ashleigh, Natsuhara, Mandy, Daniels, Gregory A., Patel, Sandip Pravin, Sacco, Assuntina Gesualda, Bykowski, Julie, Banks, Kimberly C., Cohen, Ezra E. W.
Publicado 2020

Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer

por Schwaederle, Maria, Daniels, Gregory A, Piccioni, David E, Kesari, Santosh, Fanta, Paul T, Schwab, Richard B, Shimabukuro, Kelly A, Parker, Barbara A, Kurzrock, Razelle
Publicado 2015

Telomerase Reverse Transcriptase Promoter Alterations Across Cancer Types as Detected by Next-Generation Sequencing: A Clinical and Molecular Analysis of 423 Patients

por Schwaederle, Maria, Krishnamurthy, Nithya, Daniels, Gregory A., Piccioni, David E., Kesari, Santosh, Fanta, Paul T., Schwab, Richard B., Patel, Sandip P., Parker, Barbara A., Kurzrock, Razelle
Publicado 2017

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use...

por Wong, Michael KK, Morse, Michael A, McDermott, David F, Clark, Joseph I, Kaufman, Howard L, Daniels, Gregory A, Perritt, Jessica C, Hua, Hong, Aung, Sandra
Publicado 2015

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)

por Clark, Joseph I, Morse, Michael A, Wong, Michael KK, McDermott, David F, Kaufman, Howard L, Daniels, Gregory A, Perritt, Jessica C, Hua, Hong, Aung, Sandra
Publicado 2015

Full-Length mRNA-Seq from single cell levels of RNA and individual circulating tumor cells

por Ramsköld, Daniel, Luo, Shujun, Wang, Yu-Chieh, Li, Robin, Deng, Qiaolin, Faridani, Omid R., Daniels, Gregory A., Khrebtukova, Irina, Loring, Jeanne F., Laurent, Louise C., Schroth, Gary P., Sandberg, Rickard
Publicado 2012

Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study

por Curti, Brendan D, Richards, Jon, Hyngstrom, John R, Daniels, Gregory A, Faries, Mark, Feun, Lynn, Margolin, Kim A, Hallmeyer, Sigrun, Grose, Mark, Zhang, Yiwei, Li, Anlong, Andtbacka, Robert H I
Publicado 2022

Method for estimation of apoptotic cell fraction of cytotherapy using in vivo fluorine-19 magnetic resonance: pilot study in a patient with head and neck carcinoma receiving tumor-...

por Ahrens, Eric T, Helfer, Brooke M, O’Hanlon, Charles F, Lister, Deanne R, Bykowski, Julie L, Messer, Karen, Leach, Benjamin I, Chen, Jiawen, Xu, Hongyan, Daniels, Gregory A, Cohen, Ezra E W
Publicado 2023

Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma

por Chandar, Ashwin, Silk, Ann W, Clark, Joseph I, Daniels, Gregory A, McDermott, David F, Morse, Michael, Wong, Michael KK, Stein, Mark, Mehnert, Janice, Danish, Shabbar, Aung, Sandra, Kaufman, Howard L
Publicado 2015